MedTrace Logo

Exercise, Cancer and Cognition: The ECCO-Study

NCT04789187 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2021-03-12

No results posted yet for this study

Summary

The "ECCO"-study evaluates the efficacy of simultaneous controlled exercise during neo/-adjuvant chemotherapy in breast cancer patients and its effects on neurocognition.

In this study the investigators examine the benefits of the individualized high intensity training program on a cancer related cognitive impairment.

Changes in patients' cognition are evaluated by neuropsychological testing. Possible structural changes are detected with MRI volumetry. Biomarkers connected to Cancer Related Cognitive Impairment (CRCI) and chemotherapy related inflammatory processes which impair cognition, respectively, will be assessed.

Conditions

Interventions

PROCEDURE

High-Intensity-Interval-Training

Defined exercise program up to four times per week including high-intensity-interval-training for one year of active study intervention.

PROCEDURE

General Physical Activity Recommendations

Patients will be given general physical activity recommendations during chemotherapy.

Sponsors & Collaborators

  • German Sport University, Cologne

    collaborator OTHER

  • University of Graz

    collaborator OTHER

  • Charite University, Berlin, Germany

    collaborator OTHER

  • Charles University, Czech Republic

    collaborator OTHER

  • Johannes Kepler University of Linz

    lead OTHER

Principal Investigators

  • Milan R Vosko, MD, PhD · Johannes Kepler University of Linz

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2023-12-01
Completion
2025-12-01

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04789187 on ClinicalTrials.gov